GLP-1RAs and opioid use disorder: a new frontier in addiction treatment
Glucagon-like peptide receptor agonists (GLP-1RAs) like Novo Nordisk’s semaglutide (Ozempic, Wegovy) and Eli Lilly’s ...
Many adults stop GLP-1 therapy within a year with low restart rates, analysis finds
A study conducted using electronic health record data from a collective of U.S. health care systems found that most adults ...
Lives literally depend on NIH funding for medical discovery: Pamela B. Davis
Today, my patients with cystic fibrosis live a near-normal life, but other diseases beg for NIH support. Don't halt NIH ...
Public News Service on MSN6h
GLP-1 meds offer new hope for heart health amid weight-loss craze
The GLP-1 medication trend has taken the health and wellness world by storm, largely hailed as a game-changer for weight loss ...
Medindia19h
Appetite Suppressants for Weight Loss: A Quick Fix or a Long-Term Risk?
Semaglutide (Wegovy and Ozempic): Originally developed for type 2 diabetes, this medication mimics the GLP-1 hormone, ...
Monthly Prescribing Reference22h
Many With Overweight, Obesity Discontinue GLP-1 Receptor Agonists Within One Year
HealthDay News — Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within one year, with higher discontinuation rates seen for those without ...
Cochrane23h
Does treatment with GLP-1 receptor agonists prevent complications for people with chronic kidney disease and diabetes?
• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...
Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist
Trial decision follows unanticipated events of elevated unconjugated bilirubin levelsCompany advancing multiple next-generation PTH1R agonists ...